ARVN - NASDAQ
Arvinas, Inc.
$7.70
-3.8%Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
At a Glance
Live Snapshotarvn
Cash at End of Period
Last Annual Value
142.90M
3-Year CAGR
18%
5-Year CAGR
-25%
10-Year CAGR
40%
Arvinas, Inc. Competitors Analysis of Cash at End of Period
| Company | Cash at End of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Arvinas, Inc. NASDAQ:ARVN | 142.90M | -23.3% | 4.8% | 39.6% | |
 Day One Biopharmaceuticals, Inc. NASDAQ:DAWN | 197.08M | -5.1% | -7.1% | N/A | |
 Geron Corporation NASDAQ:GERN | 79.44M | 3.7% | 17.7% | 20.0% | |
 Iovance Biotherapeutics, Inc. NASDAQ:IOVA | 169.06M | -2.3% | 14.9% | 4.7% | |
 Replimune Group, Inc. NASDAQ:REPL | 112.82M | -8.7% | -9.3% | N/A | |
 Erasca, Inc. NASDAQ:ERAS | 74.21M | -7.4% | -27.1% | N/A | |
 Astria Therapeutics, Inc. NASDAQ:ATXS | 59.82M | -30.2% | -7.1% | 9.7% | |
 Ginkgo Bioworks Holdings, Inc. NYSE:DNA | 174.23M | -44.0% | -35.8% | N/A | |
 ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP | 45.54M | -32.8% | 4.1% | N/A | |
 MeiraGTx Holdings plc NASDAQ:MGTX | 68.19M | -19.5% | -13.1% | 14.3% |
Arvinas, Inc. Fair Value Envelope
Related Guides
Continue your ARVN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.